BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22593469)

  • 1. A combined therapy with docetaxel and nedaplatin for relapsed and metastatic esophageal carcinoma.
    Matsumoto H; Hirabayashi Y; Kubota H; Murakami H; Higashida M; Haruma K; Hiratsuka J; Nakamura M; Hirai T
    Anticancer Res; 2012 May; 32(5):1827-31. PubMed ID: 22593469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer.
    Nakajima Y; Suzuki T; Haruki S; Ogiya K; Kawada K; Nishikage T; Nagai K; Kawano T
    Hepatogastroenterology; 2008; 55(86-87):1631-5. PubMed ID: 19102357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer.
    Kanekiyo S; Takeda S; Nakajima M; Nishiyama M; Kitahara M; Shindou Y; Michihisa I; Abe T; Yoshino S; Hazama S; Nagano H
    Anticancer Res; 2016 Apr; 36(4):1923-7. PubMed ID: 27069181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
    Akutsu Y; Shuto K; Kono T; Uesato M; Hoshino I; Shiratori T; Miyazawa Y; Isozaki Y; Akanuma N; Matsubara H
    Hepatogastroenterology; 2012 Oct; 59(119):2095-8. PubMed ID: 22328303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
    Jin J; Xu X; Wang F; Yan G; Liu J; Lu W; Li X; Tucker SJ; Zhong B; Cao Z; Wang D
    J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
    Tanaka T; Fujita H; Sueyoshi S; Tanaka Y; Sasahara H; Mori N; Nagano T; Yamana H; Shirouzu K
    Chemotherapy; 2007; 53(6):449-53. PubMed ID: 17952006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting.
    Osaka Y; Takagi Y; Hoshino S; Tachibana S; Tsuchida A; Aoki T
    Dis Esophagus; 2006; 19(6):473-6. PubMed ID: 17069591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
    Fujita Y; Hiramatsu M; Kawai M; Sumiyoshi K; Nishimura H; Tanigawa N
    Dis Esophagus; 2008; 21(6):496-501. PubMed ID: 18840134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
    Yoshioka T; Sakayori M; Kato S; Chiba N; Miyazaki S; Nemoto K; Shibata H; Shimodaira H; Ohtsuka K; Kakudo Y; Sakata Y; Ishioka C
    Int J Clin Oncol; 2006 Dec; 11(6):454-60. PubMed ID: 17180514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer.
    Ueda S; Kawakami H; Nishina S; Sakiyama T; Nonagase Y; Okabe T; Tamura T; Nakagawa K
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):279-85. PubMed ID: 26050210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
    Miyazaki T; Ojima H; Fukuchi M; Sakai M; Sohda M; Tanaka N; Suzuki S; Ieta K; Saito K; Sano A; Yokobori T; Inose T; Nakajima M; Kato H; Kuwano H
    Ann Surg Oncol; 2015 Oct; 22(11):3653-8. PubMed ID: 25691281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer.
    Osaka Y; Shinohara M; Hoshino S; Ogata T; Takagi Y; Tsuchida A; Aoki T
    Anticancer Res; 2011 Feb; 31(2):633-8. PubMed ID: 21378349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer.
    Miyazaki T; Sohda M; Tanaka N; Suzuki S; Ieta K; Sakai M; Sano A; Yokobori T; Inose T; Nakajima M; Fukuchi M; Ojima H; Kato H; Kuwano H
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):853-7. PubMed ID: 23306309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of docetaxel and nedaplatin combined with concurrent intensity modulated radiation therapy in the treatment of esophageal cancer].
    Bi LW; Zhang LZ; Zhao HF
    Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):710-1. PubMed ID: 23159088
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma.
    Gong Y; Ren L; Zhou L; Zhu J; Huang M; Zhou X; Wang J; Lu Y; Hou M; Wei Y
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):327-33. PubMed ID: 19048253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer].
    Fan QX; Wang R; Lu P; Zhao YF; Lu TY; Han JW; Wang JS; Luo SX; Lu SP; Wang GJ; Geng L; Zhang MZ; Ma ZY; Song M; Wu XA; Chen XB; Jiao ZM; Wang RL
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):937-9. PubMed ID: 19173998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of combination chemotherapy with docetaxel and nedaplatin for esophageal cancer].
    Kawada J; Iwase K; Deguchi K; Higashi S; Deguchi T; Matsuda C; Tamagawa H; Omori K; Nishikawa K; Nomura M; Takagi M; Fukui A; Tanaka Y
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2095-7. PubMed ID: 23267988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer.
    Kim JY; Do YR; Park KU; Kim MK; Lee KH; Bae SH; Ryoo HM; Baek JH; Song HS
    Cancer Chemother Pharmacol; 2010 May; 66(1):31-6. PubMed ID: 19763571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.